European Patent Grants for IMP731 Antibody
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Roth Capital Keeps Prima BioMed (PBMD) at 'Buy' Following Receipt of IMP731-Related European Patent
August 25, 2016 9:13 AM EDTRoth Capita affirms its Buy rating and $6 price target on Prima BioMed (Nasdaq: PBMD) after the company announced the granting of patent number 2142210 entitled Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease by the European Patent Office.
Analst Joseph Pantginis commented, We believe this patent award is an important milestone for Prima, which partnered the product with GSK, as the... More
Prima BioMed (PBMD) Announces European Patent for IMP731 Antibody
August 25, 2016 7:47 AM EDTPrima BioMed Ltd (NASDAQ: PBMD) announces the granting of patent number 2142210 entitled Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease by the European Patent Office.
The patent relates to Primas IMP731 antibody... More
